Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00343850 · ClinicalTrials.gov registry record · Phase 3
Once Daily Versus Conventional Dosing of Asacol in the Maintenance of Quiescent Ulcerative Colitis
A Phase 3 study, sponsored by University of Chicago.
- Completed
- Registry status
- Phase 3
- Development phase
- 30
- Enrollment target
NCT00343850 is a Phase 3 study that has completed, run by University of Chicago. The registered enrollment target is 30 participants.
The verdict
NCT00343850, a Phase 3 study, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if taking Asacol once a day is as effective as taking Asacol twice or three times a day in keeping ulcerative colitis inactive, and to determine which dosing regimen is easiest to follow. Once daily dosing of Asacol is experimental, and has not been approved by the FDA. Dosing as three times daily is FDA approved. This research is being done because the researchers want to learn what the best methods are for keeping ulcerative colitis inactive, and which way of taking Asacol is most helpful to subjects in continuing to take a medication to control their ulcerative colitis.
Interventions
- DRUG Asacol (mesalamine)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2006-09 |
| Est. Completion | 2007-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00343850
The ClinicalTrials.gov registry entry for NCT00343850 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Asacol (mesalamine) is the first listed.
NCT00343850 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00343850 about?
NCT00343850 is a clinical study titled "Once Daily Versus Conventional Dosing of Asacol in the Maintenance of Quiescent Ulcerative Colitis". The purpose of this study is to determine if taking Asacol once a day is as effective as taking Asacol twice or three times a day in keeping ulcerative colitis inactive, and to determine which dosing regimen is easiest to follow. Once daily dosing of Asacol is experimental, and has not been approved...
What is the current status of trial NCT00343850?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 30 participants. The study started on 2006-09. Estimated completion is 2007-03.
What interventions are being tested in trial NCT00343850?
The interventions under investigation include: Asacol (mesalamine) (DRUG).
Who is sponsoring clinical trial NCT00343850?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.